Between Leadership and Dependence: Australia’s HTA System Under Pressure

Published 8 September 2026

Australia occupies an unusual position in global pharmaceuticals. It is regarded as a leader in cost-effectiveness assessment, and at the same time it depends on innovation funded largely elsewhere. What does that dual role mean for patient access and for the medicines that reach this market?

In this episode of Cognitio, Tim Boyle presents a LifeSciences Australia Market Access Special Interest Group webinar featuring Ella O'Nuallain, a health economics and policy researcher now working at NSW Health, who interviewed ten senior leaders across government and the pharmaceutical sector for her London School of Economics dissertation.